psychiatric drugs

psychedelic art
Biotech

AbbVie pens $2B-plus neuro pact with Gilgamesh

AbbVie has inked a $2 billion biobucks deal with Gilgamesh aimed at developing next-gen therapies for psychiatric disorders.
Gabrielle Masson May 13, 2024 5:57pm
A concept image to illustrate mental health medications Models of a pink brain and two white pills which are about the size

Headlands acquires Pharmasite to expand mental health trials

Feb 29, 2024 4:20pm
IPO

Alto Neuroscience preps IPO to push CNS therapies through clinic

Jan 16, 2024 6:51am
alzheimers brain neurodegenerative memory mental health

Oryzon med fails to improve borderline personality disorder

Jan 7, 2024 4:17pm
MA strategy deal block push come together form

AbbVie pads neuroscience portfolio with $8.7B Cerevel deal

Dec 6, 2023 5:19pm
brain machine learning AI digital neuroscience

Alto's 2nd precision psychiatry med improves depression symptoms

Dec 4, 2023 5:00pm